ResearcherUniversity of PisaNo recent work listed
Lumír Kunovský
Matched on ORCID iD 0000-0003-2985-8759; OpenAlex author ID A5062752530. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 13
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper
Papers 9
- The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
- Current trends in the diagnosis of pancreatic cancer. Last author DOI 10.36290/vnl.2022.076↗
- The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines9101468↗
- Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma? Co-author DOI 10.36290/vnl.2021.011↗
- Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. Co-author DOI 10.4149/neo_2020_200408n372↗
- Risk factors of pancreatic cancer and their possible uses in diagnostics. First author DOI 10.4149/neo_2020_200706n699↗
- Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. Co-author DOI 10.4251/wjgo.v13.i8.835↗
- Pancreatic Solid Focal Lesions: Differential Diagnosis between Autoimmune Pancreatitis and Pancreatic Cancer. Last author DOI 10.1159/000499762↗
- The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Co-author DOI 10.1155/2018/5389820↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zdeněk Kala · 5 shared papers, 2018–2021 · strength 0.66
- Paper Risk factors of pancreatic cancer and their possible uses in diagnostics. DOI 10.4149/neo_2020_200706n699↗
- Paper The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. DOI 10.3390/biomedicines9101468↗
- Paper Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. DOI 10.4149/neo_2020_200408n372↗
- Michal Eid · 4 shared papers, 2021–2022 · strength 0.56
- Paper Current trends in the diagnosis of pancreatic cancer. DOI 10.36290/vnl.2022.076↗
- Paper The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. DOI 10.3390/biomedicines9101468↗
- Paper Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. DOI 10.4149/neo_2020_200408n372↗
- Jan Trna · 4 shared papers, 2018–2021 · strength 0.53
- Paper Risk factors of pancreatic cancer and their possible uses in diagnostics. DOI 10.4149/neo_2020_200706n699↗
- Paper The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. DOI 10.3390/biomedicines9101468↗
- Paper Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. DOI 10.4251/wjgo.v13.i8.835↗
- Petr Dítě DrSc · 3 shared papers, 2019–2021 · strength 0.34
- Paper Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. DOI 10.4251/wjgo.v13.i8.835↗
- Paper Is autoimmune pancreatitis a risk factor for pancreatic adenocarcinoma? DOI 10.36290/vnl.2021.011↗
- Paper Pancreatic Solid Focal Lesions: Differential Diagnosis between Autoimmune Pancreatitis and Pancreatic Cancer. DOI 10.1159/000499762↗
- Ondřej Slabý · 2 shared papers, 2021 · strength 0.25
- Jiřı́ Mayer · 2 shared papers, 2021 · strength 0.25
- Jiří Dolina · 2 shared papers, 2018–2021 · strength 0.21
- Bohuslav Kianička · 2 shared papers, 2019–2021 · strength 0.21
- Jitka Lang · 1 shared paper, 2021 · strength 0.19
- Petr Vaněk · 1 shared paper, 2022 · strength 0.19
- Jan Hlavsa · 1 shared paper, 2021 · strength 0.12
- Martina Bojková · 1 shared paper, 2021 · strength 0.12
- Arnošt Martínek · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.